ARTICLE | Clinical News
Neurocrine's valbenazine misses in Phase IIb for Tourette syndrome
December 14, 2018 6:40 PM UTC
Neurocrine Biosciences Inc. (NASDAQ:NBIX) said valbenazine missed the primary endpoint in the Phase IIb T-Force GOLD trial to treat Tourette syndrome.
In 127 pediatric patients with moderate to severe Tourette syndrome, once-daily oral valbenazine failed to significantly improve motor and phonic tic symptoms as measured by Yale Global Tic Severity Scale (YGTSS) Total Tic Score from baseline to week 12 vs. placebo...
BCIQ Company Profiles
BCIQ Target Profiles